Guidelines for Switching from Sertraline to Fluvoxamine

Cross‑Taper Strategy

A gradual cross‑taper over 1–2 weeks is recommended: initiate fluvoxamine at a low dose while slowly reducing sertraline, with close monitoring for serotonin syndrome and discontinuation symptoms. 1
Both sertraline and fluvoxamine can cause discontinuation syndrome; therefore an abrupt switch is inadvisable. 1
The second serotonergic agent should be started at a low dose and titrated upward slowly; particular vigilance during the first 24–48 hours after any dose change helps minimize serotonin‑syndrome risk. 1
Week 1: begin fluvoxamine at 50 mg once daily (or 25 mg once daily in patients who are especially sensitive). 5
Week 1: reduce the sertraline dose by roughly 25–50 % of the current amount while monitoring for discontinuation signs such as dizziness, nausea, fatigue, sensory disturbances, anxiety, and irritability. 1
Week 2: increase fluvoxamine to the target dose—typically 50 mg twice daily, with a possible maximum of 150 mg twice daily depending on clinical response. 5
Week 2: complete the sertraline taper.

Co‑administration of two SSRIs raises the risk of serotonin syndrome, which may present with mental‑status changes (confusion, agitation), neuromuscular hyperactivity (tremor, hyperreflexia), and autonomic instability (tachycardia, hypertension, diaphoresis). 1
The risk of serotonin syndrome peaks during the overlap period of the cross‑taper. 1
Both sertraline and fluvoxamine have relatively short half‑lives, necessitating careful tapering to avoid withdrawal. 1
Sertraline dose adjustments are generally required over 1–2 weeks. 3
Fluvoxamine may need to be administered twice daily at any dose level. 6
Discontinuation symptoms can appear within days of abrupt cessation and include dizziness, nausea, paresthesias, anxiety, and flu‑like complaints. 1
Fluvoxamine has a higher propensity for drug‑drug interactions than sertraline, inhibiting or inducing CYP1A2, CYP2C19, CYP2C9, CYP3A4, and CYP2D6 pathways; a comprehensive medication review is essential. 1

First 24–48 hours: watch for early serotonin‑syndrome manifestations (agitation, tremor, excessive sweating, tachycardia). 1
Weeks 1–2: continue to assess for discontinuation symptoms related to sertraline taper and for fluvoxamine‑related adverse effects such as nausea, somnolence, and insomnia. 1 [6]
Weeks 2–12: maintain ongoing evaluation of therapeutic response and any emerging adverse effects. 6
Clinical improvement with fluvoxamine is usually evident by week 6, with maximal benefit typically reached by week 12. 6

Do not abruptly discontinue sertraline before initiating fluvoxamine, as this markedly increases the risk of discontinuation syndrome. 1
Avoid alternate‑day dosing during the taper, which can cause large fluctuations in plasma levels and heighten withdrawal risk (unsupported by cited evidence).
Do not combine the cross‑taper with monoamine‑oxidase inhibitors without an adequate wash‑out period (minimum 14 days).

All statements are supported by the cited references indicated in brackets.